References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
DPP-4 is a key modulator of the incretin system, and functions to catalytically inactivate GLP-1 and GIP
I prioritized moderate portions of fresh, whole food (in addition to cottage cheese, I sometimes craved meat) and ate to nourish my body
While the ingredient profiles are the same (more on that later), there actually is a big difference
STEP 4 is the important counterpoint: weight came back when treatment stopped, so this is a long-term treatment rather than a short course, and whether it is right for you is a decision for the prescribing doctor